[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-383641-105":59,"doc-detail-383641-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-advances-in-the-treatment-of-gastroesophageal-cancers","Therapeutic Advances in the Treatment of Gastroesophageal Cancers","","Gastroesophageal cancers are aggressive and inherently heterogeneous, leading to poor prognosis across subtypes. Esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma differ in molecular biology, affecting actionable targets and treatment response. Multimodality therapy is required for localized disease, and management for advanced or metastatic disease should be biomarker-driven when appropriate. Current FDA-approved options include HER2-targeted therapy, immunotherapy, and chemotherapy, while emerging targeted strategies and future personalized treatment rely on molecular profiling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-advances-in-the-treatment-of-gastroesophageal-cancers/383641/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-advances-in-the-treatment-of-gastroesophageal-cancers/383641.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which gastroesophageal cancer subtypes are highlighted, and why do they matter for treatment?","Question",{"text":112,"@type":113},"The review focuses on esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma. Their distinct molecular biology can influence available targets and expected treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment approach is described for localized versus advanced or metastatic disease?",{"text":117,"@type":113},"Localized disease requires multimodality therapy, with decisions supported by multidisciplinary discussions. For unresectable or metastatic disease, care relies on palliative systemic therapies and, when appropriate, biomarker-driven systemic treatment.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the current FDA-approved systemic options, and what is changing in newer therapies?",{"text":121,"@type":113},"Current FDA-approved treatments include HER2-targeted therapy, immunotherapy, and chemotherapy. The review notes that novel molecular targets are under development and that future therapy will increasingly be personalized based on molecular profiling.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},383641,1790639563,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","biomolecules  \nReview  \nTherapeutic Advances in the Treatment of  \nGastroesophageal Cancers  \nJenny J. Li 1, Jane E. Rogers 2, Kohei Yamashita 1,3, Rebecca E. Waters 4, Mariela Blum Murphy 1 and Jaffer A. Ajani 1, *  \n1 Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA; [jjli2@mdanderson.org](jjli2@mdanderson.org) (J.J.L.)  \n2 Department of Pharmacy Clinical Program, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA  \n3 Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan  \n4 Department of Pathology, Division of Pathology/Lab Medicine, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA  \n* [Correspondence: jajani@mdanderson.org](Correspondence: jajani@mdanderson.org)  \nCitation: Li, J.J.; Rogers, J.E.; Yamashita, K.; Waters, R.E.; Blum Murphy, M.; Ajani, J.A. Therapeutic Advances in the Treatment of Gastroesophageal Cancers. Biomolecules 2023, 13, 796. [https://](https://)[ ](https://)[doi.org/10.3390/biom13050796](doi.org/10.3390/biom13050796)  \nAcademic Editors: Amir Avanand Elisa Giovannetti  \nReceived: 1 April 2023  \nRevised: 2 May 2023  \nAccepted: 4 May 2023  \nPublished: 6 May 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nAbstract: Gastroesophageal cancers are a group of aggressive malignancies that are inherently heterogeneous with poor prognosis. Esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma all have distinct underlying molecular biology, which can impact available targets and treatment response. Multimodality therapy is needed in the localized setting and treatment decisions require multidisciplinary discussions. Systemic therapies for treatment of advanced/metastatic disease should be biomarker-driven, when appropriate. Current FDA approved treatments include HER2-targeted therapy, immunotherapy, and chemotherapy. However, novel therapeutic targets are under development and future treatments will be personalized based on molecular profiling. Herein, we review the current treatment approaches and discuss promising advances in targeted therapies for gastroesophageal cancers.  \nKeywords: esophageal cancer; gastric cancer; immunotherapy; targeted therapy  \n1. Introduction  \nGastroesophageal cancers, including cancers of the esophagus, gastroesophageal junction (GEJ), and stomach, represent some of the most common cancers worldwide, with an estimated 1.7 million new cases per year. When combined, they are the third leading cause of cancer-related deaths globally [1] . Esophageal cancers are comprised of two major histologic subtypes: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) . While ESCC is the most common subtype worldwide, EAC is more common in the Western countries [2] . ESCC is mainly found in the upper to mid esophagus and is associated with tobacco and alcohol use, whereas EAC is mostly found in the distal esophagus and is associated with obesity, gastroesophageal reflux, and Barrett's esophagus [3,4] . In addition to differences in risk factors and locations, these two subtypes also have distinct molecular biology and responses to treatment, which should lead to different treatment strategies [5] . In contrast, GEJ and gastric cancers are almost all adenocarcinomas (ACs) . Gastric adenocarcinomas (GACs) can be further classified into intestinal and diffuse histologic subtypes based on Lauren classification [6] . The Cancer Genome Atlas Research Netwo","cbCaia4bsj47UHEO","https://ap.wps.com/l/cbCaia4bsj47UHEO","pdf",314746,16,"English","# Introduction\n# Localized Disease","[{\"question\":\"Which gastroesophageal cancer subtypes are highlighted, and why do they matter for treatment?\",\"answer\":\"The review focuses on esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, and gastric adenocarcinoma. Their distinct molecular biology can influence available targets and expected treatment response.\"},{\"question\":\"What treatment approach is described for localized versus advanced or metastatic disease?\",\"answer\":\"Localized disease requires multimodality therapy, with decisions supported by multidisciplinary discussions. For unresectable or metastatic disease, care relies on palliative systemic therapies and, when appropriate, biomarker-driven systemic treatment.\"},{\"question\":\"What are the current FDA-approved systemic options, and what is changing in newer therapies?\",\"answer\":\"Current FDA-approved treatments include HER2-targeted therapy, immunotherapy, and chemotherapy. The review notes that novel molecular targets are under development and that future therapy will increasingly be personalized based on molecular profiling.\"}]","Therapeutic Advances in the Treatment of Gastroesophageal Cancers | PDF",1790258520]